Themis Bioscience and the Institut Pasteur announce positive chikungunya vaccine results in phase I using revolutionary measles vector Vienna-based Themis Bioscience, and the Paris based Institut Pasteur announced earlier this week a successful phase I trial of their revolutionary chikungunya vaccine. The phase 1 trial of 42 subjects demonstrated the vaccine to be well tolerated and safe. The trial also …
Themis Bioscience’s Vaccine against Chikungunya Successful in Phase 1
Results presented at international conferences in Philadelphia and New Orleans November 20, 2014 The induction of neutralizing antibodies by a prophylactic Chikungunya vaccine candidate has now been confirmed by the final results of a phase 1 clinical trial, as well as its tolerability and safety. Detailed information of the trial has been presented at two international conferences. The vaccine candidate …
30 Years of HIV: but who made the discovery?
It has been 30 years to the day since Dr Robert Gallo, MD and colleagues from the Institute of Human Virology at the University of Maryland announced at a press conference that they had discovered the cause of AIDS: HIV Gallo’s announcement 30 years ago came at a trying time across the world as the only recently described AIDS was …